US Stock MarketDetailed Quotes
FGEN FibroGen
- 0.387
- +0.037+10.63%
Close Nov 21 16:00 ET
- 0.378
- -0.009-2.35%
Post 20:01 ET
39.02MMarket Cap-314P/E (TTM)
0.389High0.337Low1.33MVolume0.337Open0.350Pre Close487.70KTurnover1.43%Turnover RatioLossP/E (Static)100.77MShares2.93052wk High-0.16P/B36.02MFloat Cap0.18052wk Low--Dividend TTM93.03MShs Float68.550Historical High--Div YieldTTM14.94%Amplitude0.180Historical Low0.366Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
FibroGen Stock Forum
hope you can perform again 💪💪💪
FibroGen Inc - Study Did Not Meet Primary Endpoint
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials
No comment yet